These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38988318)

  • 1. Current and emerging drug treatment strategies to tackle sickle cell anemia.
    Persaud Y; Leonard A; Rai P
    Expert Opin Emerg Drugs; 2024 Jul; ():1-20. PubMed ID: 38988318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease.
    Bhatt S; Argueta DA; Gupta K; Kundu S
    Antioxid Redox Signal; 2024 Jun; 40(16-18):1025-1049. PubMed ID: 37975291
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials.
    Ross JM; Forté S; Soulières D
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):211-224. PubMed ID: 35912835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the diagnosis and treatment of sickle cell disease.
    Brandow AM; Liem RI
    J Hematol Oncol; 2022 Mar; 15(1):20. PubMed ID: 35241123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
    Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
    Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging pharmacotherapeutic approaches for the management of sickle cell disease.
    Torres L; Conran N
    Expert Opin Pharmacother; 2019 Feb; 20(2):173-186. PubMed ID: 30499731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of sickle cell disease - options and perspective.
    Abdel-Hadi L; Ventura Carmenate Y; Castillo-Aleman YM; Sheikh S; Zakaria A; Phillips J
    Am J Blood Res; 2023; 13(2):61-70. PubMed ID: 37214647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
    Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
    Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
    Ansari J; Moufarrej YE; Pawlinski R; Gavins FNE
    Expert Rev Hematol; 2018 Jan; 11(1):45-55. PubMed ID: 29207881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?
    Tayyaba Rehan S; Hussain HU; Malik F; Usama RM; Tahir MJ; Asghar MS
    Health Sci Rep; 2022 Jul; 5(4):e713. PubMed ID: 35774831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?
    Leibovitch JN; Tambe AV; Cimpeanu E; Poplawska M; Jafri F; Dutta D; Lim SH
    Blood Rev; 2022 May; 53():100925. PubMed ID: 34991920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.
    Barak M; Hu C; Matthews A; Fortenberry YM
    Cells; 2024 May; 13(10):. PubMed ID: 38786070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations.
    Obadina M; Wilson S; Derebail VK; Little J
    Kidney360; 2023 Jul; 4(7):997-1005. PubMed ID: 37254256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective.
    Dela-Pena JC; King MA; Brown J; Nachar VR
    J Oncol Pharm Pract; 2022 Apr; 28(3):646-663. PubMed ID: 35060419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes.
    Khan SJ; Zaidi SAT; Murtaza SF; Asif M; Kumar V
    Cureus; 2023 Aug; 15(8):e42847. PubMed ID: 37664319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
    Migotsky M; Beestrum M; Badawy SM
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to increase access to basic sickle cell disease care in low- and middle-income countries.
    Dua M; Bello-Manga H; Carroll YM; Galadanci AA; Ibrahim UA; King AA; Olanrewaju A; Estepp JH
    Expert Rev Hematol; 2022 Apr; 15(4):333-344. PubMed ID: 35400264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voxelotor for the treatment of sickle cell disease.
    Vissa M; Vichinsky E
    Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.